First clinical experience in 14 patients treated with ADVOS: a study on feasibility, safety and efficacy of a new type of albumin dialysis

Table 3 Treatment data and outcome

	Treat-ment time [min] [19]	Serum bilirubin [mg/dl]				Serum creatinine [mg/dl]				Serum BUN [mg/dl]				No. of treatments	28d survival
		Day before ADVOS	Before start of ADVOS	After ADVOS	Delta [mg/dl]	Day before ADVOS	Before start of ADVOS	After ADVOS	Delta [mg/dl]	Day before ADVOS	Before start of ADVOS	After ADVOS	Delta [mg/dl]
Patient
P1	745	37.4	41.1	25.4	−15.7	0.7	0.8	0.5	−0.3	59	76	28	−48	19	-
P2	800	22.8	24.0	12.8	−11.2	1.0	1.0	0.9	−0.1	26	25	14	−11	10	-
P3	730	20.8	22.3	14.1	−8.2	1.8	1.6	1.5	−0.1	21	20	18	−2	7	-
P4	770	16.3	15.9	13.2	−2.7	2.4	1.9	1.5	−0.4	27	20	18	−2	29	-
P5	800	n.d.	11.6	9.2	−2.4	n.d.	2.8	1.2	−1.6	n.d.	45	13	−32	3	-
P6	600	43.5	41.6	34.2	−7.4	3.9	3.3	2.2	−1.1	91	97	63	−34	22	+
P7	720	3.1	5.3	3.9	−1.4	1.7	3.0	2.1	−0.9	19	33	22	−11	17	+
P8	420	21.6	20.7	17.8	−2.9	1.3	2.0	2.8	+0.8	44	69	82	+13	9	-
P9	570	26.4	26.2	20.3	−5.9	1.9	2.3	1.7	−0.6	43	51	35	−16	6	+
P10	300	1.9	2.0	1.5	−0.5	1.7	1.3	0.7	−0.6	54	31	16	−15	1	-
P11	240	40.4	41.6	29.0	−12.6	3.0	3.2	2.0	−01.2	35	40	27	−13	101	+
P12	510	18.3	17.5	10.9	−6.6	1.4	2.9	2.1	−0.8	40	49	27	−22	3	-
P13	360	38.2	42.1	19.9	−22.2	3.0	2.3	1.2	−1.1	79	68	33	−35	11	+
P14	480	49.3	51.8	35.7	−16.1	3.0	3.0	2.2	−0.8	54	67	39	−28	1	-
Mean ± SD Number [%]	575± 193	26.2± 14.9	26.0± 15.4	17.7± 10.5	−8.3± 6.5	2.0± 0.9	2.2± 0.8	1.6± 0.7	−0.6± 0.6	46± 22	49± 23	31± 20	−18± 16	17± 26 [1–101]	5/14 [36%]

ADVOS advanced organ support
BUN blood urea nitrogen
n.d. not done
Delta absolute changes when comparing values immediately before and after the first ADVOS session